CRISPR Therapeutics (NASDAQ:CRSP) Issues Earnings Results

CRISPR Therapeutics (NASDAQ:CRSP) released its quarterly earnings results on Monday. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.06) by ($0.09), FiscalAI reports. The company had revenue of $12.67 million for the quarter, compared to the consensus estimate of $14.75 million. CRISPR Therapeutics had a negative net margin of 1,812.07% and a negative return on equity of 24.96%. CRISPR Therapeutics’s revenue was up 1311.1% compared to the same quarter last year.

CRISPR Therapeutics Stock Up 3.1%

CRSP opened at $50.07 on Friday. The company has a quick ratio of 17.85, a current ratio of 17.85 and a debt-to-equity ratio of 0.34. CRISPR Therapeutics has a 12-month low of $44.12 and a 12-month high of $63.45. The firm’s fifty day moving average price is $53.28 and its 200 day moving average price is $52.81.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 47,837 shares of the stock in a transaction on Monday, October 19th. The stock was sold at an average price of $49.78, for a total value of $2,381,325.86. Following the sale, the chief executive officer directly owned 311,899 shares of the company’s stock, valued at $15,526,332.22. This trade represents a 13.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel James R. Kasinger sold 1,040 shares of the company’s stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $49.26, for a total transaction of $51,230.40. Following the completion of the transaction, the general counsel owned 95,857 shares of the company’s stock, valued at approximately $4,721,915.82. This trade represents a 1.07% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 93,558 shares of company stock valued at $4,881,663 over the last three months. 5.20% of the stock is currently owned by company insiders.

Key CRISPR Therapeutics News

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Citigroup raised its price target on CRISPR Therapeutics, a potentially supportive signal for investor sentiment; the report did not provide the new target in the available details. Citigroup price target report
• Positive Sentiment: Brookline Capital Markets substantially improved its forecasts, revising projected losses to $4.74 per share for FY2026 from $5.63 and to $3.83 for FY2027 from $4.51. HC Wainwright also made smaller upward adjustments to several quarterly and annual estimates and maintains a Buy rating. Better-than-previous forecasts could support the shares, although losses remain expected. Brookline Capital Markets comments CRISPR Therapeutics analyst estimates
• Neutral Sentiment: RBC Capital assigned CRISPR Therapeutics a Hold rating, indicating a more cautious view than the Buy calls but not a direct downgrade. RBC Capital Hold rating
• Neutral Sentiment: CRSP is attracting increased attention among Zacks.com users, but the “trending stock” coverage does not itself report a new business or clinical development. Zacks trending-stock article

Analysts Set New Price Targets

CRSP has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating on shares of CRISPR Therapeutics in a report on Friday, October 9th. UBS Group began coverage on shares of CRISPR Therapeutics in a research note on Thursday, October 15th. They issued a “neutral” rating and a $52.00 price objective for the company. Needham & Company LLC restated a “buy” rating and set a $82.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday. Citigroup increased their target price on CRISPR Therapeutics from $88.00 to $90.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, William Blair raised shares of CRISPR Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $69.69.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company’s research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.

Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.